A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe

See also
Status	Clinical Trial	Phase
Completed	`NCT01194219` - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Phase 3
Recruiting	`NCT06030076` - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed	`NCT04263610` - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy	Phase 4
Completed	`NCT02601469` - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05600036` - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05375955` - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.	Phase 2
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Not yet recruiting	`NCT05036889` - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.	N/A
Completed	`NCT04603027` - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis	Phase 2
Completed	`NCT03638258` - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis	Phase 2
Completed	`NCT02881346` - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting	`NCT02611349` - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT02251678` - Evaluate the Effect of Elimune Capsules	Phase 1
Completed	`NCT01987843` - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Terminated	`NCT01708629` - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects	Phase 3
Completed	`NCT01230138` - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis	Phase 2
Withdrawn	`NCT00747032` - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT00581100` - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis	Phase 4
Suspended	`NCT01228656` - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate	Phase 2
Completed	`NCT00540618` - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis	Phase 2

NCT number	NCT02634801
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	January 20, 2016
Completion date	November 14, 2017

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms